Edesa Biotech (EDSA) Stock Price, News & Analysis

Company Overview

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. The company’s research programs are primarily directed toward dermatological and respiratory conditions for which existing treatment options may be limited.

Edesa’s lead product candidate, EB01, is a topical, nonsteroidal anti-inflammatory therapy being developed for chronic hand eczema. The company has also developed EB05, an investigational antibody intended to modulate inflammatory responses associated with acute respiratory distress syndrome and other serious inflammatory conditions.

Founded in 2015, Edesa Biotech is headquartered in Markham, Ontario, Canada, and has conducted development activities in North America. The company is led by Par Nijhawan, who serves as chief executive officer and has been involved in the company’s formation and biotechnology operations.

Key Stats

• Today's Range: $2.57 to $2.73
• 50-Day Range: $2.57 to $5.75
• 52-Week Range: $0.72 to $20.32
• Volume: 25,765 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Edesa Biotech Stock Analysis - MarketRank™

Edesa Biotech scored higher than 79% of companies evaluated by MarketBeat, and ranked 192nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Edesa Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Edesa Biotech has a consensus price target of $5.00, representing about 90.1% upside from its current price of $2.63.

Amount of Analyst Coverage

Edesa Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Edesa Biotech are expected to grow in the coming year, from ($1.99) to ($1.96) per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.21% of the float of Edesa Biotech has been sold short.

Short Interest Ratio / Days to Cover

Edesa Biotech has a short interest ratio ("days to cover") of 3.51, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edesa Biotech has recently decreased by 20.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edesa Biotech does not currently pay a dividend.

Dividend Growth

Edesa Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Edesa Biotech has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Edesa Biotech this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for EDSA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Edesa Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Edesa Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.40% of the stock of Edesa Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

5.50% of the stock of Edesa Biotech is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 12/11/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EDSA
• CIK: 1540159
• Web: www.edesabiotech.com
• Phone: (905) 475-1234
• Fax: 805-488-2889
• Employees: 17
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Edesa Biotech: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +90.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 7,289,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A